These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28887129)
1. Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity. Hasinoff BB; Patel D Arch Biochem Biophys; 2017 Nov; 633():23-28. PubMed ID: 28887129 [TBL] [Abstract][Full Text] [Related]
2. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs. Hasinoff BB; Patel D Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728 [TBL] [Abstract][Full Text] [Related]
3. Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome. Hasinoff BB Arch Biochem Biophys; 2018 Feb; 639():52-58. PubMed ID: 29305052 [TBL] [Abstract][Full Text] [Related]
4. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1. Fan Y; You G Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809 [TBL] [Abstract][Full Text] [Related]
5. Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs. Henriques de Jesus CS; Chiorcea-Paquim AM; Barsan MM; Diculescu VC Talanta; 2019 Jul; 199():32-39. PubMed ID: 30952265 [TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413 [TBL] [Abstract][Full Text] [Related]
7. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288 [TBL] [Abstract][Full Text] [Related]
8. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug. Tundo GR; Sbardella D; Oddone F; Grasso G; Marini S; Atzori MG; Santoro AM; Milardi D; Bellia F; Macari G; Graziani G; Polticelli F; Cascio P; Parravano M; Coletta M Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204815 [TBL] [Abstract][Full Text] [Related]
9. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression. Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Lövborg H; Oberg F; Rickardson L; Gullbo J; Nygren P; Larsson R Int J Cancer; 2006 Mar; 118(6):1577-80. PubMed ID: 16206267 [TBL] [Abstract][Full Text] [Related]
11. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Skrott Z; Cvek B Mini Rev Med Chem; 2012 Oct; 12(12):1184-92. PubMed ID: 22931589 [TBL] [Abstract][Full Text] [Related]
12. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts. Han J; Liu L; Yue X; Chang J; Shi W; Hua Y Toxicol Appl Pharmacol; 2013 Dec; 273(3):477-83. PubMed ID: 24060341 [TBL] [Abstract][Full Text] [Related]
13. The Proteasome as a Drug Target in the Metazoan Pathogen, Bibo-Verdugo B; Wang SC; Almaliti J; Ta AP; Jiang Z; Wong DA; Lietz CB; Suzuki BM; El-Sakkary N; Hook V; Salvesen GS; Gerwick WH; Caffrey CR; O'Donoghue AJ ACS Infect Dis; 2019 Oct; 5(10):1802-1812. PubMed ID: 31355632 [TBL] [Abstract][Full Text] [Related]
14. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790 [TBL] [Abstract][Full Text] [Related]
15. Comparative mechanisms of action of proteasome inhibitors. Wang M Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479 [TBL] [Abstract][Full Text] [Related]
16. Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. Li L; Yang H; Chen D; Cui C; Dou QP Toxicol Appl Pharmacol; 2008 Jun; 229(2):206-14. PubMed ID: 18304598 [TBL] [Abstract][Full Text] [Related]
17. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines. Altundag EM; Yilmaz AM; Sahin A; Yilmaz BK Anticancer Agents Med Chem; 2022 Aug; 22(16):2909-2918. PubMed ID: 35352669 [TBL] [Abstract][Full Text] [Related]
18. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Stein RL; Melandri F; Dick L Biochemistry; 1996 Apr; 35(13):3899-908. PubMed ID: 8672420 [TBL] [Abstract][Full Text] [Related]
19. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527 [TBL] [Abstract][Full Text] [Related]
20. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Cvek B; Dvorak Z Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]